J Cancer 2019; 10(10):2161-2168. doi:10.7150/jca.26727

Research Paper

HLA Polymorphisms And TKI-Induced Liver Injury in Patients with Cancer: A Meta-analysis

Qian Xiang1, Zhuo Zhang1, Yingchao Wu2, Shuai Zuo2, Qianxin Liu1, Tao Liu2, Xin Wang2, Yimin Cui1✉

1. Department of Pharmacy, Peking University First Hospital, No. 6, Dahongluochang Street, Xicheng District, Beijing 100034, China
2. Department of General Surgery, Peking University First Hospital, No. 8, Xishikuda Street, Xicheng District, Beijing 100034, China

Abstract

Background: Tyrosine kinase inhibitors (TKIs) are widely used for patients with cancer, although liver injury has been observed in a small proportion of these patients. The aim of this study was to investigate the mechanisms underlying TKI-induced liver injury according to HLA polymorphisms.

Methods: We systematically searched three electronic databases (PubMed, PMC, EmBase, and the Cochrane library) to identify studies that evaluated the impact of HLA polymorphisms on the incidence of TKI-induced liver injury in cancer patients as of November 2018. The summary odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Further, sensitivity analysis and publication bias assessments were also performed.

Results: In the final analysis, four studies that involved a total of 12,181 patients were included. Three of the studies included patients who received lapatinib, and the other study included patients who received pazopanib. Overall, carriers of HLA-DQA1*02:01 were associated with an increased risk of liver injury (OR: 6.85; 95%CI: 2.34-20.02; P<0.001). Furthermore, HLA-DQB1*02:02 was correlated with a greater risk of liver injury (OR: 5.61; 95%CI: 2.80-11.25; P<0.001). Finally, HLA-DRB1*07:01 was significantly correlated with a greater risk of liver injury (OR: 4.06; 95%CI: 2.33-7.09; P<0.001).

Conclusions: The findings of this meta-analysis confirmed that three polymorphisms of HLA were significantly associated with an increased risk of TKI-induced liver injury. Further work will be required to determine these relationships in patients with specific characteristics.

Keywords: Tyrosine kinase inhibitors, liver injury, HLA, polymorphisms

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Xiang Q, Zhang Z, Wu Y, Zuo S, Liu Q, Liu T, Wang X, Cui Y. HLA Polymorphisms And TKI-Induced Liver Injury in Patients with Cancer: A Meta-analysis. J Cancer 2019; 10(10):2161-2168. doi:10.7150/jca.26727. Available from http://www.jcancer.org/v10p2161.htm